Trial Profile
An Open Label, Phase Ib, Dose-escalation Study Evaluating the Safety and Tolerability of Xentuzumab and Abemaciclib in Patients With Locally Advanced or Metastatic Solid Tumours and in Combination With Endocrine Therapy in Patients With Locally Advanced or Metastatic Hormone Receptor-positive, HER2-, Breast Cancer, Followed by Expansion Cohorts
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 08 Mar 2024
Price :
$35
*
At a glance
- Drugs Abemaciclib (Primary) ; Xentuzumab (Primary) ; Anastrozole; Fulvestrant; Letrozole
- Indications Advanced breast cancer; HER2 negative breast cancer; Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Boehringer Ingelheim
- 04 Mar 2024 Planned End Date changed from 15 Apr 2024 to 30 May 2024.
- 12 Dec 2023 Planned End Date changed from 29 Dec 2023 to 15 Apr 2024.
- 08 Aug 2023 Planned End Date changed from 24 Aug 2023 to 29 Dec 2023.